AnMed Health Cancer Center

Summary

AnMed Health Cancer Center is a medical facility located in Anderson, South Carolina. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Ovarian Cancer, Lymphoma and other specialties. AnMed Health Cancer Center is involved with conducting 243 clinical trials across 282 conditions. There are 4 research doctors associated with this hospital, such as John E. Doster, David Griffin, Jay B. Nayak, and Leander Cannick.

Top PIs

Clinical Trials running at AnMed Health Cancer Center

Bladder Cancer

Lung Cancer

Colorectal Cancer

Pancreatic Cancer

Breast Cancer

Non-Small Cell Lung Cancer

Cancer

Melanoma

Lymphoma

Prostate Cancer

Gemcitabine + Docetaxel vs BCG

for Bladder Cancer

This trial is testing whether a combination of two drugs, Gemcitabine and Docetaxel, given directly into the bladder, is effective for patients with high-grade non-muscle invasive bladder cancer who have not been treated with the standard therapy before. The goal is to see if this new treatment can prevent cancer from coming back or spreading. The study will also look at the quality of life, safety, and side effects of the new treatment. Gemcitabine and Docetaxel have shown promise as an alternative treatment, especially in cases where the standard therapy fails or is not tolerated.

Recruiting

2 awards

Phase 3

14 criteria

Blood Test and Immunotherapy

for Bladder Cancer

This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. In this study, a blood test is used to measure ctDNA and see if there is still cancer somewhere in the body after surgery and if giving a treatment will help eliminate the cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, can help the body's immune system to attack the cancer, and can interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine if ctDNA measurement in blood can better identify patients that need additional treatment, if treatment with nivolumab prolongs patients' life and whether the additional immunotherapy treatment with relatlimab extends time without disease progression or prolongs life of urothelial cancer patients who have undergone surgical removal of their bladder, kidney, ureter or urethra.

Recruiting

1 award

Phase 2 & 3

10 criteria

Blood Sample Collection

for Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

Recruiting

1 award

N/A

9 criteria